Brigatinib in Crizotinib-Refractory ALK+ Non–Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
Huber, Rudolf M., Hansen, Karin H., Paz-Ares Rodríguez, Luis, West, Howard L., Reckamp, Karen L., Leighl, Natasha B., Tiseo, Marcello, Smit, Egbert F., Kim, Dong-Wan, Gettinger, Scott N., Hochmair, MaLanguage:
english
Journal:
Journal of Thoracic Oncology
DOI:
10.1016/j.jtho.2019.11.004
Date:
November, 2019
File:
PDF, 393 KB
english, 2019